Dr. Andrew Walkty
  Assistant Professor, Departments of Medical Microbiology and Internal Medicine, University of Manitoba

Degrees: BSc Pharm ( Manitoba , 1999), M.D. ( Manitoba , 2003), FRCPC Internal Medicine ( Manitoba , 2007), FRCPC Infectious Diseases ( Manitoba , 2008), FRCPC Medical Microbiology ( Manitoba , 2009)

Mailing Address:  MS673B, Microbiology, Health Sciences Centre
820 Sherbrook St ., Winnipeg , Manitoba , Canada, R3A 1R9

Tel: (204) 787-1161
E-mail: AWalkty@hsc.mb.ca

Dr. Walkty is not currently accepting graduate students.

Research Interests:
Antimicrobial resistance, including antimicrobial susceptibility and mechanisms of resistance

Recent Publications:

For a list of Dr. Walkty's PubMed articles, please click here

  1. Walkty A, Van Caeseele P, Hilderman T, Buchan S, Weiss E, Sloane M, Fatoye B. Mumps in prison: description of an outbreak in Manitoba, Canada. Can J Public Health 2011;102:241-4.

  2. Walkty A, Abbott B, Swirsky N, Safneck J. Keeping an open mind about meningitis: a case report of carcinomatous meningitis. CJEM 2011;13:352-6.

  3. Hatakka A, Klein J, He R,  Piper J, Tam E, Walkty A. Acute hepatitis as a manifestation of parvovirus B19 infection. J Clin Microbiol 2011;49:3422-4.

  4. Karlowsky JA, Lagace-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD. Antimicrob Agents Chemother 2011;55:3169-75.

  5. Walkty A, DeCorby M, Lagace-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 Study).  Antimicrob Agents Chemother 2011;55:2992-4.

  6. Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2011;55:2434-7.

  7. Walkty A, Adam HJ, Laverdiere M, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69:348-55.